NCT04727853View on ClinicalTrials.gov

Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

April 26, 2022

Study Completion Date

April 26, 2022

Conditions
Small Cell Lung Cancer (SCLC)
Interventions
DRUG

irinotecan liposome injection

Drug: irinotecan liposome injection

Trial Locations (1)

130012

Jilin Cancer Hospital, Changchun

Sponsors
All Listed Sponsors
lead

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

NCT04727853 - Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC) | Biotech Hunter | Biotech Hunter